Asset

ROXADUSTAT

Kyntra Bio Inc. Common Stock

Revenue

No revenue reported in loaded filings.

Clinical trials (6)

NCT IDPhaseStatusStartCompletionSponsor nameTitle
NCT03303066phase2_3completed2018-06-062023-01-11Kyntra BioEfficacy and Safety of FG-4592 for Treatment of Anemia in Participants With Lower Risk Myelodysplastic Syndrome (MDS)
NCT02652806phase3completed2015-12-012017-01-24Kyntra BioFG-4592 for Treatment of Anemia in Subjects With Chronic Kidney Disease
NCT02652819phase3completed2015-12-012017-01-24Kyntra BioFG-4592 for Treatment of Anemia in Subjects With Chronic Kidney Disease Not on Dialysis
NCT01599507phase2completed2011-12-012013-01-01Kyntra BioStudy of FG-4592 in Subjects With Chronic Kidney Disease in China
NCT01596855phase2completed2011-09-012013-01-01Kyntra BioStudy of FG-4592 in Subjects With End-Stage Renal Disease Receiving Maintenance Hemodialysis in China

FDA applications (0)

This company has no applications containing this asset.

Marketed products (0)